{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:13:45Z","timestamp":1788556425657,"version":"build-2803163510"},"reference-count":81,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"US Food and Drug Administration","doi-asserted-by":"publisher","award":["R01FD007483"],"award-info":[{"award-number":["R01FD007483"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018488","name":"Clinical and Translational Science Institute, University of Florida","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018488","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["1R61 NS135019-01A1"],"award-info":[{"award-number":["1R61 NS135019-01A1"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.omta.2026.201681","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T15:47:44Z","timestamp":1769701664000},"page":"201681","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Design and initial characterization of a novel mini-promoter for gene therapies targeting the central nervous system"],"prefix":"10.1016","volume":"34","author":[{"given":"Monika","family":"Chauhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey L.","family":"Daugherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh (Ellie)","family":"Khadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozgun F.","family":"Duzenli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Tinklenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Aslanidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7430-124X","authenticated-orcid":false,"given":"Christina A.","family":"Pacak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201681_bib1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omta.2026.201681_bib2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2174\/1566523223666230331111336","article-title":"Mammalian Stable Cell Platforms for Recombinant Adeno-associated Virus (rAAV) Production: Development Strategies and their Impact on Viral Productivity","volume":"23","author":"Fernandes","year":"2023","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.omta.2026.201681_bib3","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1089\/hum.2020.182","article-title":"Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy","volume":"31","author":"Wilson","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201681_bib4","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1089\/hum.2022.29211.bfs","article-title":"Food and Drug Administration Lifts Clinical Hold on Pfizer Duchenne Muscular Dystrophy Gene Therapy Linked to Patient Death","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201681_bib5","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.omta.2026.201681_bib6","first-page":"91","article-title":"Sarepta's DMD gene therapy falls flat","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omta.2026.201681_bib7","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1089\/hum.2020.187","article-title":"AAV Vectors: Are They Safe?","volume":"31","author":"Srivastava","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201681_bib8","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1186\/s12967-024-05599-5","article-title":"AAV-DJ is superior to AAV9 for targeting brain and spinal cord, and de-targeting liver across multiple delivery routes in mice","volume":"22","author":"Chauhan","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omta.2026.201681_bib9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.omtm.2019.08.010","article-title":"Targeting Adeno-Associated Virus Vectors for Local Delivery to Fractures and Systemic Delivery to the Skeleton","volume":"15","author":"Lee","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201681_bib10","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2021-050360","article-title":"Metronidazole-Induced Hepatitis in a Teenager With Xeroderma Pigmentosum and Trichothiodystrophy Overlap","volume":"148","author":"Abiona","year":"2021","journal-title":"Pediatrics"},{"key":"10.1016\/j.omta.2026.201681_bib11","article-title":"Hepatic Failure following Metronidazole in Children with Cockayne Syndrome","volume":"2020","author":"Ataee","year":"2020","journal-title":"Case Rep. Pediatr."},{"key":"10.1016\/j.omta.2026.201681_bib12","article-title":"Metronidazole-induced hepatotoxicity in a patient with xeroderma pigmentosum: A case report","volume":"101","author":"Vanoli","year":"2022","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.omta.2026.201681_bib13","doi-asserted-by":"crossref","first-page":"e706","DOI":"10.1542\/peds.2015-0531","article-title":"Metronidazole Toxicity in Cockayne Syndrome: A Case Series","volume":"136","author":"Wilson","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.omta.2026.201681_bib14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41434-023-00411-3","article-title":"Sildenafil increases AAV9 transduction after a systemic administration and enhances AAV9-dystrophin therapeutic effect in mdx mice","volume":"31","author":"Zhou","year":"2024","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201681_bib15","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.3390\/jcm10112471","article-title":"Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia","volume":"10","author":"Monahan","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.omta.2026.201681_bib16","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201681_bib17","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201681_bib18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.omtm.2022.07.018","article-title":"Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper","volume":"26","author":"Yang","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201681_bib19","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201681_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25021050","article-title":"Delivery of Adeno-Associated Virus Vectors to the Central Nervous System for Correction of Single Gene Disorders","volume":"25","author":"Daci","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omta.2026.201681_bib21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1479-0556-6-13","article-title":"Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice","volume":"6","author":"Pacak","year":"2008","journal-title":"Genet. Vaccines Ther."},{"key":"10.1016\/j.omta.2026.201681_bib22","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1089\/hum.2023.209","article-title":"Intravitreal Delivery of rAAV2-hSyn-hRS1 Results in Retinal Ganglion Cell-Specific Gene Expression and Retinal Improvement in the Rs1-KO Mouse","volume":"35","author":"Zheng","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201681_bib23","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.ymthe.2020.03.007","article-title":"AAV Capsid-Promoter Interactions Determine CNS Cell-Selective Gene Expression In Vivo","volume":"28","author":"Powell","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201681_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/978-1-61779-370-7_6","article-title":"AAV-mediated liver-directed gene therapy","volume":"807","author":"Sands","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omta.2026.201681_bib25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1089\/hum.2018.020","article-title":"AAV-Mediated TAZ Gene Replacement Restores Mitochondrial and Cardioskeletal Function in Barth Syndrome","volume":"30","author":"Suzuki-Hatano","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201681_bib26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1046\/j.1432-1327.1998.2580123.x","article-title":"Transcriptional regulation of the tissue-type plasminogen-activator gene in human endothelial cells: identification of nuclear factors that recognise functional elements in the tissue-type plasminogen-activator gene promoter","volume":"258","author":"Costa","year":"1998","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.omta.2026.201681_bib27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1101\/gad.12.1.34","article-title":"New core promoter element in RNA polymerase II-dependent transcription: sequence-specific DNA binding by transcription factor IIB","volume":"12","author":"Lagrange","year":"1998","journal-title":"Genes Dev."},{"key":"10.1016\/j.omta.2026.201681_bib28","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ydbio.2009.08.009","article-title":"Regulation of gene expression via the core promoter and the basal transcriptional machinery","volume":"339","author":"Juven-Gershon","year":"2010","journal-title":"Dev. Biol."},{"key":"10.1016\/j.omta.2026.201681_bib29","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1101\/gr.104471.109","article-title":"Homotypic clusters of transcription factor binding sites are a key component of human promoters and enhancers","volume":"20","author":"Gotea","year":"2010","journal-title":"Genome Res."},{"key":"10.1016\/j.omta.2026.201681_bib30","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3390\/v12040460","article-title":"Battling Neurodegenerative Diseases with Adeno-Associated Virus-Based Approaches","volume":"12","author":"Mijanovic","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.omta.2026.201681_bib31","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/jgm.516","article-title":"Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle","volume":"6","author":"Brooks","year":"2004","journal-title":"J. Gene Med."},{"key":"10.1016\/j.omta.2026.201681_bib32","first-page":"3325","article-title":"Comparison of the EF-1 alpha and the CMV promoter for engineering stable tumor cell lines using recombinant adeno-associated virus","volume":"22","author":"Teschendorf","year":"2002","journal-title":"Anticancer Res."},{"key":"10.1016\/j.omta.2026.201681_bib33","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41434-019-0075-6","article-title":"Astrocyte-selective AAV gene therapy through the endogenous GFAP promoter results in robust transduction in the rat spinal cord following injury","volume":"26","author":"Griffin","year":"2019","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201681_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/cells12121619","article-title":"A Novel Small NPC1 Promoter Enhances AAV-Mediated Gene Therapy in Mouse Models of Niemann-Pick Type C1 Disease","volume":"12","author":"Hughes","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.omta.2026.201681_bib35","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s44321-024-00037-x","article-title":"Improved gene therapy for spinal muscular atrophy in mice using codon-optimized hSMN1 transgene and hSMN1 gene-derived promotor","volume":"16","author":"Xie","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omta.2026.201681_bib36","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1089\/hum.1996.7.17-2101","article-title":"Quantitative analysis of the packaging capacity of recombinant adeno-associated virus","volume":"7","author":"Dong","year":"1996","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201681_bib37","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200309","article-title":"Cognitive Decline and Other Late-Stage Neurologic Complications in Cockayne Syndrome","volume":"14","author":"Rajamani","year":"2024","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.omta.2026.201681_bib38","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/ng.2653","article-title":"The Genotype-Tissue Expression (GTEx) project","volume":"45","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omta.2026.201681_bib39","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1101\/gr.100370.109","article-title":"Sequence features that drive human promoter function and tissue specificity","volume":"20","author":"Landolin","year":"2010","journal-title":"Genome Res."},{"key":"10.1016\/j.omta.2026.201681_bib40","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.omtm.2023.05.013","article-title":"Strong ubiquitous micro-promoters for recombinant adeno-associated viral vectors","volume":"29","author":"Chai","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201681_bib41","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1089\/hum.2017.069","article-title":"Design of a Novel Gene Therapy Construct to Achieve Sustained Brain-Derived Neurotrophic Factor Signaling in Neurons","volume":"29","author":"Osborne","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201681_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd2590","article-title":"Receptor-ligand supplementation via a self-cleaving 2A peptide-based gene therapy promotes CNS axonal transport with functional recovery","volume":"7","author":"Khatib","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omta.2026.201681_bib43","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41586-024-07710-8","article-title":"Split intein-mediated protein trans-splicing to express large dystrophins","volume":"632","author":"Tasfaout","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.omta.2026.201681_bib44","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1089\/hum.2010.245","article-title":"Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors","volume":"22","author":"Gray","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201681_bib45","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/gt.2012.43","article-title":"Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial","volume":"20","author":"Gaudet","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201681_bib46","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/mt.2014.200","article-title":"A phase 1\/2a follistatin gene therapy trial for becker muscular dystrophy","volume":"23","author":"Mendell","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201681_bib47","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0006-8993(95)01488-8","article-title":"Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector","volume":"713","author":"McCown","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.omta.2026.201681_bib48","doi-asserted-by":"crossref","first-page":"S212","DOI":"10.1002\/jgm.506","article-title":"Recombinant AAV-mediated gene delivery to the central nervous system","volume":"6","author":"Tenenbaum","year":"2004","journal-title":"J. Gene Med."},{"key":"10.1016\/j.omta.2026.201681_bib49","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/sj.gt.3301221","article-title":"Influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain","volume":"7","author":"Paterna","year":"2000","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201681_bib50","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1006\/exnr.1997.6736","article-title":"Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors","volume":"150","author":"Klein","year":"1998","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.omta.2026.201681_bib52","first-page":"116","article-title":"Better Targeting, Better Efficiency for Wide-Scale Neuronal Transduction with the Synapsin Promoter and AAV-PHP","volume":"9","author":"Jackson","year":"2016","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.omta.2026.201681_bib53","first-page":"637","article-title":"Promoter analysis of RPE65, the gene encoding a 61-kDa retinal pigment epithelium-specific protein","volume":"39","author":"Nicoletti","year":"1998","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omta.2026.201681_bib54","doi-asserted-by":"crossref","first-page":"19064","DOI":"10.1074\/jbc.M309881200","article-title":"Analysis of the VMD2 promoter and implication of E-box binding factors in its regulation","volume":"279","author":"Esumi","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omta.2026.201681_bib55","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.preteyeres.2014.08.001","article-title":"Vector platforms for gene therapy of inherited retinopathies","volume":"43","author":"Trapani","year":"2014","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.omta.2026.201681_bib56","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.1093\/nar\/27.24.4775","article-title":"Use of the human EF-1alpha promoter for expression can significantly increase success in establishing stable cell lines with consistent expression: a study using the tetracycline-inducible system in human cancer cells","volume":"27","author":"Gopalkrishnan","year":"1999","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omta.2026.201681_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106472","article-title":"A comparative analysis of constitutive promoters located in adeno-associated viral vectors","volume":"9","author":"Damdindorj","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.omta.2026.201681_bib58","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/sj.gt.3301561","article-title":"Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor 1alpha promoter","volume":"8","author":"Gill","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.omta.2026.201681_bib59","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.plasmid.2012.07.003","article-title":"Assessment of the long-term transcriptional activity of a 550-bp-long human beta-actin promoter region","volume":"68","author":"Damdindorj","year":"2012","journal-title":"Plasmid"},{"key":"10.1016\/j.omta.2026.201681_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010611","article-title":"Systematic comparison of constitutive promoters and the doxycycline-inducible promoter","volume":"5","author":"Qin","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.omta.2026.201681_bib61","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0378-1119(02)00878-8","article-title":"Generation of a synthetic mammalian promoter library by modification of sequences spacing transcription factor binding sites","volume":"297","author":"Tornoe","year":"2002","journal-title":"Gene"},{"key":"10.1016\/j.omta.2026.201681_bib62","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146286","article-title":"AAV9\/MFSD8 gene therapy is effective in preclinical models of neuronal ceroid lipofuscinosis type 7 disease","volume":"132","author":"Chen","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omta.2026.201681_bib63","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1089\/hum.2016.013","article-title":"Novel Vector Design and Hexosaminidase Variant Enabling Self-Complementary Adeno-Associated Virus for the Treatment of Tay-Sachs Disease","volume":"27","author":"Karumuthil-Melethil","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201681_bib64","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41583-024-00829-7","article-title":"Gene therapy for CNS disorders: modalities, delivery and translational challenges","volume":"25","author":"Gao","year":"2024","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.omta.2026.201681_bib65","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1186\/s12967-024-05661-2","article-title":"Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside","volume":"22","author":"Xu","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omta.2026.201681_bib66","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/0-306-46825-5_9","article-title":"Regulation of the hypoxia-inducible factor-1 alpha. ARNT is not necessary for hypoxic induction of HIF-1 alpha in the nucleus","volume":"475","author":"Gassmann","year":"2000","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.omta.2026.201681_bib67","first-page":"205","article-title":"Evaluation of promoters for use in tissue-specific gene delivery","volume":"434","author":"Zheng","year":"2008","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omta.2026.201681_bib68","article-title":"CRISPR-Cas9: Transforming Functional Genomics, Precision Medicine, and Drug Development - Opportunities, Challenges, and Future Directions","author":"Khan","year":"2025","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.omta.2026.201681_bib69","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune Responses to Viral Gene Therapy Vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201681_bib70","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3389\/fimmu.2019.00874","article-title":"Gene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected Individuals","volume":"10","author":"Thiebaut","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201681_bib71","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-1-62703-284-1_7","article-title":"Promoter deletion analysis using a dual-luciferase reporter system","volume":"977","author":"Xu","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omta.2026.201681_bib72","first-page":"159","article-title":"Does not hUTP14a promoter form a regulation feedback loop with P53?","volume":"26","author":"Zhang","year":"2014","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.omta.2026.201681_bib73","doi-asserted-by":"crossref","DOI":"10.3791\/2538","article-title":"High-efficiency transduction of liver cancer cells by recombinant adeno-associated virus serotype 3 vectors","author":"Ling","year":"2011","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.omta.2026.201681_bib74","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.omtm.2023.01.006","article-title":"Tumor antigen-loaded AAV vaccine drives protective immunity in a melanoma animal model","volume":"28","author":"Krotova","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201681_bib75","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/icb.2013.74","article-title":"Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy","volume":"92","author":"Pandya","year":"2014","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.omta.2026.201681_bib76","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1089\/hum.2020.074","article-title":"Modifiers of Adeno-Associated Virus-Mediated Gene Expression in Implication for Serotype-Universal Neutralizing Antibody Assay","volume":"31","author":"Krotova","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201681_bib77","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1161\/01.RES.0000237661.18885.f6","article-title":"Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo","volume":"99","author":"Pacak","year":"2006","journal-title":"Circ. Res."},{"key":"10.1016\/j.omta.2026.201681_bib78","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/0006-8993(81)90203-1","article-title":"Intrathecal substance P elicits a caudally-directed biting and scratching behavior in mice","volume":"217","author":"Hylden","year":"1981","journal-title":"Brain Res."},{"key":"10.1016\/j.omta.2026.201681_bib79","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1016\/j.ymthe.2023.09.018","article-title":"Intrathecal delivery of AAV-NDNF ameliorates disease progression of ALS mice","volume":"31","author":"Cheng","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201681_bib80","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0014-2999(80)90515-4","article-title":"Intrathecal morphine in mice: a new technique","volume":"67","author":"Hylden","year":"1980","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.omta.2026.201681_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2021.100725","article-title":"An optimized intracerebroventricular injection of CD4(+) T cells into mice","volume":"2","author":"Taylor","year":"2021","journal-title":"STAR Protoc."},{"key":"10.1016\/j.omta.2026.201681_bib82","doi-asserted-by":"crossref","first-page":"7060","DOI":"10.1038\/s41467-023-42809-y","article-title":"Lipofuscin-like autofluorescence within microglia and its impact on studying microglial engulfment","volume":"14","author":"Stillman","year":"2023","journal-title":"Nat. Commun."}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26000169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26000169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:29:35Z","timestamp":1788553775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26000169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S3117387X26000169"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201681","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and initial characterization of a novel mini-promoter for gene therapies targeting the central nervous system","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201681","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201681"}}